ASCEND BY NTHRYS
Research Abroad Products

Molecular Oncology Project Topics

Browse all focused areas across all project categories under this field.

Showing 13–24 of 220 project topics
Multi-Panel Oncogene Profiling and Risk Stratification Service
Commercial laboratory testing service that analyzes 50+ oncogenes simultaneously with integrated risk scoring and clinical interpretation reports. Generates revenue through per-sample testing fees and premium interpretation packages for oncology clinics.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Competitive Oncogene Landscape Intelligence and Monetization Platform
SaaS platform tracking oncogene prevalence, mutation hotspots, and drug target opportunities across cancer types using aggregated public and proprietary genomic data. Monetizes through enterprise subscriptions to biotech and pharma companies conducting target selection and competitive analysis.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Integrated TP53 and BRCA Mutation Reporting Commercial Suite
End-to-end commercial reporting platform specializing in clinically actionable TP53 and BRCA variant interpretation with automated accreditation-compliant documentation. Drives revenue through laboratory information system integration and certification-based licensing fees.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Somatic vs Germline Oncogene Classification Decision Support Tool
AI-powered diagnostic tool that automatically classifies oncogenic mutations as somatic or germline origin with clinical and hereditary cancer risk context. Creates revenue through clinical laboratory licensing, genetic counselor workflows, and EHR integration partnerships.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Custom Tumor Suppressor Gene Panel Design and Validation Service
Commercial consulting and bioinformatics service that designs, validates, and deploys custom gene panels targeting specific tumor suppressor genes for precision oncology programs. Generates revenue through design fees, validation studies, and per-panel implementation licensing.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Clonal Evolution and Oncogene Driver Dominance Tracking Platform
Specialized SaaS application that monitors clonal heterogeneity and dominant oncogenic drivers across serial tumor samples using liquid biopsy and tissue data. Serves oncology clinics and clinical trial sponsors through subscription licensing and data integration services.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Oncogene Actionability and Drug Sensitivity Matching Engine
Commercial precision medicine platform matching detected oncogenic mutations to available targeted therapies and clinical trials using curated drug databases. Monetizes through clinical usage fees, pharmaceutical partnerships, and trial enrollment optimization services.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
Tumor Suppressor Inactivation Mechanism Deep Analysis Commercial Tool
Advanced analytics platform that decodes tumor suppressor inactivation mechanisms (point mutations, deletions, epigenetic silencing) across sample cohorts for mechanistic insight. Supports commercial drug development workflows and generates revenue through research licensing and collaboration models.
Oncogene & Tumor Suppressor Analytics Platforms Click to view more details →
AI-Powered Tumor Mutational Burden Prediction Platform
A cloud-based SaaS platform that uses machine learning algorithms to predict tumor mutational burden (TMB) from genomic sequencing data in real-time. This enables oncologists to identify immunotherapy candidates faster, improving patient stratification and reducing time-to-treatment by 40-60%.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Next-Generation Biomarker Discovery and Validation Service
A comprehensive service offering that combines genomic analysis, bioinformatics, and clinical validation to identify and validate companion diagnostic biomarkers for oncology drug development. Pharmaceutical companies gain accelerated FDA approval pathways and de-risked companion diagnostic adoption, reducing development timelines by 18-24 months.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Liquid Biopsy Companion Diagnostic Integration Platform
An integrated software platform that standardizes and automates companion diagnostic testing using circulating tumor DNA (ctDNA) and cell-free DNA from blood samples. Healthcare systems and labs achieve 3-5x higher throughput, lower cost-per-test, and improved patient compliance through non-invasive monitoring.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
HLA Typing and Personalized Immunotherapy Matching Tool
A diagnostic tool that performs high-resolution HLA typing and matches patients to optimal CAR-T cell and checkpoint inhibitor therapies based on genetic compatibility. This precision matching service increases therapeutic efficacy rates by 25-35% and reduces adverse event rates, commanding premium pricing from health systems.
Molecular Oncology Companion Diagnostic Dev Click to view more details →